Relationship between mitotic index and Ki67 expression in meningioma

Background: Meningioma is the most common primary central nervous system (CNS) tumor which covers 36.4% of all CNS tumors. Two important factors determining the prognosis of patients with a diagnosis of meningioma are the percentage of tumor resection and the degree of tumor histopathology. Because there are limitations to routine histopathological examination in predicting tumor progressivity, several examination techniques have been developed including cytogenetics and use of immunohistochemical examination.Method: Observational analytic study was carried out on 68 tumor samples in dr. Wahidin Sudirohusodo Hospital and the Makassar Pathology Diagnostic Center with diagnoses of meningioma from 2012-2018. The Sample size is determined by consecutive sampling method.Results: Sample Size were 68 people from Dr. Wahidin Sudirohusodo Hospital and the Makassar Pathology Diagnostic Center with diagnoses of meningioma which fulfilled the inclusion criteria and consisted of 19(27.9%) men and 49 (72.1%) women with an average age of 42 years. The most common location of the tumor was in the convexity area with an incidence of 29.4%. Grade I meningioma was found 41.2%, grade II of 32.4% and grade III of 26.5%. In grade I, the mean mitotic index was 0.25, grade II was (7.4) and grade III was 22.75. In grade I, the mean Ki67 expression was 1.01%. The highest expression was obtained in grade III with amean of 14.8% and the highest expression was 53%. The Spearman’s rho test results between the mitotic index and Ki67 expression show that there is a positive correlation of 0.490, which means that there is a moderate correlation.Conclusion: IHC expression of Ki67 increases proportionally to the degree of histopathology of meningioma. There is a positive correlation of 0.490 which means that there is a moderate correlation between the mitotic index and Ki67 expression.

Luminal B. Factor pronóstico y predictivo del Ki67 / Luminal B. Prognostic and predictive factor of Ki67

Introducción El cáncer de mama es una enfermedad heterogénea; tumores con factores pronósticos similares presentan diferente evolución, lo que hace suponer que la diferencia es molecular. El antígeno de proliferación celular Ki67 es un factor clave que representa la actividad mitótica celular. Objetivos Analizar el subtipo Luminal B y el valor del Ki67, evaluando su relación con los factores pronósticos y predictivos clásicos, y determinar su utilidad para subclasificar grupos moleculares en función del mismo. Material y métodos Estudio descriptivo, retrospectivo, analítico observacional. Se revisaron 520 fichas de patología mamaria pertenecientes al Hospital Churruca y al Sanatorio Corporación Médica General San Martín, en el período comprendido entre enero 2010-enero 2015. Fueron analizadas 82 pacientes subtipo Luminal B, con Ki67 elevado. Resultados La mediana de expresión del Ki67 fue de 25,9% y del 34% en las pacientes recaídas. Discusión Se observó relación proporcional del Ki67 con el tamaño tumoral y el grado histológico. Conclusiones El Ki67 debe ser analizado en la práctica diaria por patólogos expertos, a fin de predecir el comportamiento frente a tratamientos adyuvantes de una manera más certera, adecuando la terapéutica a cada paciente.

Introduction Breast cancer is a heterogeneous disease; tumors with similar prognostic factors have different evolution, which suggests that the difference is at the molecular level. The proliferation antigen Ki67 is a key factor that represents the cell mitotic activity. Objectives Analyze Luminal B subtype and the value of Ki67, evaluating its relationship with prognostic and predictive factors conventionally used. Determine its usefulness for subclassified different molecular groups. Matherials and method Observational analytical retrospective study. We reviewed 520 breast cancer files belonging to Churruca Hospital and Sanatorio Corporación Médica General San Martín in the period between January 2010- January 2015. We analyzed 82 patients Luminal B subtype with hight Ki67. Results The median expression of Ki67 was 25.9 % and 34% in patients with relapsed. Discussion We found proportional relationship between the value of Ki67 with tumor size and histologic hight grade. Conclusions The Ki67 must be analyzed in daily practice validated by expert pathologists in late predict behavior towards adjuvant treatments in a more accurate way available, adapting to each patient therapeutic methods.

The research progress in preoperative evaluation of diffusion kurtosis imaging in glioma grading and correlation with Ki-67 expression / 中国基层医药

Recently diverse magnetic resonance imaging technology is used in glioma grading,which based on the theory of Gaussian distribution.Diffusion kurtosis imaging emerges as an extension of DWI and DTI,which could reflect the real and actual hydron non-Gaussion distribution of tumor and peritumoral microenvironment.Displaying the correlation with immunohistochemical label Ki-67,DKI convinces more scholars inland and abroad with its practicability.

Role of ultrasonography and Ki-67 expression in evaluation of neoadjuvant chemotherapy for breast can- cer / 实用医学杂志

Objective To analyze the changes of ultrasonography and Ki-67 before and after neoadjuvant chemotherapy for breast cancer ,and to assess the value of ultrasonography and Ki-67 in the evaluation of neoadju-vant chemotherapy for breast cancer. Methods The focus changes of 122 cases of breast cancer before and after neoadjuvant chemotherapy were observed by Color Doppler ultrasonography. The therapeutic effect was evaluated by RECIST standard,and the changes of Ki-67 before and after chemotherapy were observed. Results There were significant differences in size and internal blood flow signal of breast cancer before and after chemotherapy (P <0.05). The sensitivity of ultrasonography in the evaluation of neoadjuvant chemotherapy for breast cancer was 89.3%and specificity 53.8%. The clinical efficiency of neoadjuvant chemotherapy for breast cancer with high Ki-67 expression was higher than that with low Ki-67 expression. Conclusion Ultrasonography shows high clinical value in the evaluation of neoadjuvant chemotherapy for breast cancer ,and the expression of Ki-67 could predict the effi-cacy of neoadjuvant chemotherapy.